Skip to main content
ENDO 2026 Main banner

Diabetes and Vascular Disease

SUN-662 - Risk Factors for Early-Onset Type 2 Diabetes in Mexico: The Role of Paternal History, Obesity, and Metabolic Inflammation

Sunday, June 14, 2026
9:00 AM - 4:00 PM CT
Location: ENDOExpo; Poster Floor
Disclosure(s):
Maria Elena Romero Ibarguengoitia, MD, PHD: No financial relationships to disclose


Background: Early-onset type 2 diabetes mellitus (T2DM) is increasing worldwide, representing a growing public health challenge. However, data regarding risk factors in the Mexican population remain limited.

Objective: To identify risk factors associated with early-onset T2DM (diagnosis before 40 years of age) in a Mexican population.

Methods: We conducted a retrospective, age- and sex-matched case–control study. Clinical, familial, anthropometric, and biochemical data were obtained from medical records of patients attending a clinic in northwestern Mexico between 2017 and 2025. Logistic regression analysis was performed to identify factors associated with early-onset T2DM.

Results: A total of 258 participants were included, equally distributed between cases and controls. The overall median age (IQR) was 32 (5) years, and 146 participants (56.6%) were male. Multivariable logistic regression identified paternal history of T2DM (OR 4.29; p=0.04), neutrophil levels (OR 1.93; p< 0.001), lymphocyte levels (OR 2.48; p=0.03), liver risk score (OR 8.80; p< 0.001), and body mass index (BMI) (OR 1.13; p=0.005) as independent predictors of early-onset T2DM (Nagelkerke’s R² = 0.818).

Conclusions: Early-onset T2DM in this Mexican population is strongly associated with paternal family history and metabolic-inflammatory factors, including systemic inflammation, metabolic dysfunction–associated steatotic liver disease (MASLD), and obesity. These findings highlight the importance of early identification and targeted intervention addressing inflammation, MASLD, and obesity to reduce the risk of T2DM at younger ages.

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*